Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy

被引：3
|
作者：
Bychkovsky, Brittany L. [1 ,2 ]
Dizon, Don S. [2 ,3 ]
Sikov, William M. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA
[4] Brown Univ, Alpert Med Sch, Women & Infants Hosp Rhode Isl, Program Womens Oncol, Providence, RI 02912 USA
来源：
CLINICAL OBSTETRICS AND GYNECOLOGY | 2016年 / 59卷 / 04期
关键词：
breast cancer; chemotherapy; endocrine therapy; biological agents; adjuvant therapy; neoadjuvant therapy; PATHOLOGICAL COMPLETE REMISSION; CONTROLLED SUPERIORITY TRIAL; PACLITAXEL PLUS TRASTUZUMAB; PHASE-II TRIAL; OPEN-LABEL; COMPLETE RESPONSE; RANDOMIZED-TRIAL; FOLLOW-UP; STAGE-II; BEVACIZUMAB;
D O I：
10.1097/GRF.0000000000000237
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Breast cancer is a heterogenous disease, comprised of at least 3 major subtypes: hormone receptor-positive/HER2-(HR+), HER2+, and HR-/HER2-(triple negative) breast cancers. The medical management of each subype is distinct. In this article, we review contemporary data supporting the use of chemotherapy, endocrine therapy and biologic therapies, especially HER2-directed agents, in the adjuvant and neoadjuvant setting in patients with newly diagnosed nonmetastatic (stage I-III) breast cancer.
引用
收藏
页码：756 / 771
页数：16
相关论文
共 50 条
  • [1] ADJUVANT AND NEOADJUVANT TREATMENT OF BREAST-CANCER WITH CHEMOTHERAPY AND OR ENDOCRINE THERAPY
    BONADONNA, G
    VALAGUSSA, P
    BRAMBILLA, C
    MOLITERNI, A
    ZAMBETTI, M
    FERRARI, L
    [J]. SEMINARS IN ONCOLOGY, 1991, 18 (06) : 515 - 524
  • [2] Adjuvant systemic therapies for patients with breast cancer: Endocrine responsiveness and effects of chemotherapy
    不详
    [J]. CURRENT PROBLEMS IN CANCER, 2003, 27 (01) : 13 - 16
  • [3] Adjuvant and neoadjuvant systemic therapy for breast cancer
    Schmid, P
    Possinger, K
    [J]. INTERNIST, 2002, 43 (03): : 341 - +
  • [4] Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
    Rodrigo Goncalves
    Cynthia Ma
    Jingqin Luo
    Vera Suman
    Matthew James Ellis
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 223 - 229
  • [5] Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
    Goncalves, Rodrigo
    Ma, Cynthia
    Luo, Jingqin
    Suman, Vera
    Ellis, Matthew James
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (04) : 223 - 229
  • [6] Controversies in the use of endocrine adjuvant therapies of breast cancer
    Ingle, James N.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 40 - 40
  • [7] Neoadjuvant use of endocrine therapy in breast cancer
    Macaskill, E. Jane
    Dixon, J. Michael
    [J]. BREAST JOURNAL, 2007, 13 (03): : 243 - 250
  • [8] ADJUVANT ENDOCRINE THERAPY AND CHEMOTHERAPY OF BREAST-CANCER
    HEUSON, JC
    PARIDAENS, R
    [J]. LOUVAIN MEDICAL, 1982, 101 (10): : 617 - 626
  • [9] Role of adjuvant endocrine therapy in breast cancer
    Neskovic-Konstantinovic, Z
    [J]. 2ND BALKAN CONGRESS OF ONCOLOGY, 1999, : 157 - 162
  • [10] ENDOCRINE THERAPY IN BREAST CANCER: THE NEOADJUVANT, ADJUVANT, AND METASTATIC APPROACH
    Reinbolt, Raquel E.
    Mangini, Neha
    Hill, Jordan L.
    Levine, Lauren B.
    Dempsey, Jessica L.
    Singaravelu, Janani
    Koehler, Kevin A.
    Talley, Allison
    Lustberg, Maryam B.
    [J]. SEMINARS IN ONCOLOGY NURSING, 2015, 31 (02) : 146 - 155
12345